TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Motor Task-Specific Therapy Synchronized With Vibrotactile Cueing on Sensorimotor Performance of Upper Extremity for the Chronic Stroke Patients
Brief Summary: The investigator assumed that perturbed-event-induced vibrotactile cueing enable more precision arm movement adjustment, sensory function and dexterity improvement in the spastic arm. Thus the specific aim of the study was to develop a vibrotactile therapy system that can provide vibrotactile feedback through the pinch performance of the hand when countering mechanically induced perturbations and also analyzed training effects of the perturbation-based pinch task training system on the sensorimotor performance of the hands for stroke patients.


Options:
A: Arm Label: Intensive group; Type: EXPERIMENTAL; Interventions: Procedure: Cognitive rehabilitation | Arm Label: Conventional group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cognitive rehabilitation | Intervention Type: PROCEDURE; Name: Cognitive rehabilitation; Assigned to Arm(s): Conventional group, Intensive group
B: Arm Label: Action Training; Type: ACTIVE_COMPARATOR; Interventions: Other: Action Training | Arm Label: tDCS; Type: EXPERIMENTAL; Interventions: Other: Transcranial direct current stimulation | Arm Label: Action Training + tDCs; Type: EXPERIMENTAL; Interventions: Other: Transcranial direct current stimulation, Other: Action Training | Arm Label: Control training; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: OTHER; Name: Transcranial direct current stimulation; Assigned to Arm(s): Action Training + tDCs, tDCS | Intervention Type: OTHER; Name: Action Training; Assigned to Arm(s): Action Training, Action Training + tDCs
C: Arm Label: Vibratory perturbed task-specific movement training; Type: EXPERIMENTAL; Interventions: Other: Vibratory perturbed task-specific movement training, Other: Sensorimotor training | Arm Label: Traditional task-oriented facilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional task-oriented facilitation, Other: Sensorimotor training | Intervention Type: OTHER; Name: Vibratory perturbed task-specific movement training; Assigned to Arm(s): Vibratory perturbed task-specific movement training | Intervention Type: OTHER; Name: Traditional task-oriented facilitation; Assigned to Arm(s): Traditional task-oriented facilitation | Intervention Type: OTHER; Name: Sensorimotor training; Assigned to Arm(s): Traditional task-oriented facilitation, Vibratory perturbed task-specific movement training
D: Arm Label: Optimization of OKS; Type: EXPERIMENTAL; Interventions: Device: OKS | Arm Label: Safety and efficacy study; Type: EXPERIMENTAL; Interventions: Device: OKS | Arm Label: Effect of repetitive stimulation; Type: EXPERIMENTAL; Interventions: Device: OKS | Arm Label: OKS and gait; Type: EXPERIMENTAL; Interventions: Device: OKS | Intervention Type: DEVICE; Name: OKS; Assigned to Arm(s): Effect of repetitive stimulation, OKS and gait, Optimization of OKS, Safety and efficacy study

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Identify the Effect and the Working Mechanisms of MyPlan 2.0, a Self-regulation-based e- and mHealth Intervention Targeting Physical Activity and Sedentary Behaviour, in Older Adults
Brief Summary: The aim of this study is to investigate whether and how 'MyPlan 2.0' helps older adults to be more physically active or less sedentary. Two groups will be created, an intervention group and a waiting-list control group.


Options:
A: Arm Label: FlexToBa physical activity DVD; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based, DVD-delivered physical activity | Arm Label: Usual care-Wait list; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care/Wait list | Intervention Type: BEHAVIORAL; Name: Home-based, DVD-delivered physical activity; Assigned to Arm(s): FlexToBa physical activity DVD | Intervention Type: BEHAVIORAL; Name: Usual care/Wait list; Assigned to Arm(s): Usual care-Wait list
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: MyPlan 2.0 | Arm Label: Waiting List control group; Type: EXPERIMENTAL; Interventions: Other: Waiting List | Intervention Type: BEHAVIORAL; Name: MyPlan 2.0; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Waiting List; Assigned to Arm(s): Waiting List control group
C: Arm Label: REACH Participant Course; Type: EXPERIMENTAL; Interventions: Behavioral: REACH | Intervention Type: BEHAVIORAL; Name: REACH; Assigned to Arm(s): REACH Participant Course
D: Arm Label: MIPARC intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity, Behavioral: Group educational sessions, Behavioral: Phone counseling call, Behavioral: Peer Mentoring, Behavioral: Policy Change, Behavioral: Support, Behavioral: Tailored environmental resources | Arm Label: Health Education Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group educational sessions, Behavioral: Health check phone call, Behavioral: Pedometer | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Group educational sessions; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Phone counseling call; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Peer Mentoring; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Policy Change; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Support; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Tailored environmental resources; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Group educational sessions; Assigned to Arm(s): Health Education Control | Intervention Type: BEHAVIORAL; Name: Health check phone call; Assigned to Arm(s): Health Education Control | Intervention Type: BEHAVIORAL; Name: Pedometer; Assigned to Arm(s): Health Education Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Oral Vitamin D Supplementation in Egyptian Infants With Acute Bronchiolitis Improve the Outcome? A Double Blind Randomized Controlled Trial
Brief Summary: This study was conducted to evaluate the effect of oral vitamin D supplementation on the clinical course of acute bronchiolitis, and to investigate whether vitamin D deficiency among infants who required hospital-based care for bronchiolitis is associated with the severity of the acute episode.


Options:
A: Arm Label: Single, high dose oral vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3, Dietary Supplement: Standard Vitamin D3 Supplementation | Arm Label: Standard Vitamin D Supplementation; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard Vitamin D3 Supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Single, high dose oral vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard Vitamin D3 Supplementation; Assigned to Arm(s): Single, high dose oral vitamin D3, Standard Vitamin D Supplementation
B: Arm Label: Devit-3 Oral Drop 400 IU; Type: OTHER; Interventions: Drug: Devit-3 Oral Drop | Arm Label: Devit-3 Oral Drop 800 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Devit-3 Oral Drop | Arm Label: Devit-3 Oral Drop 1000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Devit-3 Oral Drop | Intervention Type: DRUG; Name: Devit-3 Oral Drop; Assigned to Arm(s): Devit-3 Oral Drop 1000 IU, Devit-3 Oral Drop 400 IU, Devit-3 Oral Drop 800 IU
C: Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: monitored group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: monitored vit D supplementation | Arm Label: standard group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard vit D supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: monitored vit D supplementation; Assigned to Arm(s): monitored group | Intervention Type: DIETARY_SUPPLEMENT; Name: standard vit D supplementation; Assigned to Arm(s): standard group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2, Randomized, Open-Label, Active-Controlled, Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects Converting From Epoetin Alfa (FO2RWARD-2)
Brief Summary: This is a Phase 2 open-label efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) study to evaluate oral Vadadustat for the treatment of anemia in hemodialysis participants converting from Epoetin Alfa therapy.


Options:
A: Arm Label: Vadadustat; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Vadadustat TIW; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat TIW | Arm Label: Epoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin Alfa | Intervention Type: DRUG; Name: Vadadustat TIW; Assigned to Arm(s): Vadadustat TIW
B: Arm Label: ASP1517 Low dose Group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: ASP1517 High dose Group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Intervention Type: DRUG; Name: roxadustat; Assigned to Arm(s): ASP1517 High dose Group, ASP1517 Low dose Group
C: Arm Label: AKB-6548 240 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: AKB-6548 370 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: AKB-6548 500 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: AKB-6548 630 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AKB-6548; Assigned to Arm(s): AKB-6548 240 mg, AKB-6548 370 mg, AKB-6548 500 mg, AKB-6548 630 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: GSK1278863 10 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 15 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 25 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 30 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: GSK1278863 matching Placebo | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): GSK1278863 10 mg, GSK1278863 15 mg, GSK1278863 25 mg, GSK1278863 30 mg | Intervention Type: DRUG; Name: GSK1278863 matching Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Vitamin K Antagonists Versus Rivaroxaban in Hemodialysis Patients With Atrial Fibrillation: a Multicenter Randomized Controlled Trial
Brief Summary: The investigators refer to the trial with clinicaltrials.gov indentifier NCT02610933 entitled Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients.

After termination of this trial, included patients will be asked to participate in the extension trial by continuing the treament of their respective allocation arm. No new intervention will be done.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin K Antagonist - Drug | Arm Label: rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet | Arm Label: rivaroxaban + K2; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet, Dietary Supplement: MK-7 2000µg thrice weekly | Intervention Type: DRUG; Name: Rivaroxaban 10 MG Oral Tablet; Assigned to Arm(s): rivaroxaban, rivaroxaban + K2 | Intervention Type: DIETARY_SUPPLEMENT; Name: MK-7 2000µg thrice weekly; Assigned to Arm(s): rivaroxaban + K2 | Intervention Type: DRUG; Name: Vitamin K Antagonist - Drug; Assigned to Arm(s): Control
B: Arm Label: Apixaban 2.5 mg twice daily and standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban 2.5 milligram Oral Tablet | Arm Label: Standard of care and no anticoagulation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Apixaban 2.5 milligram Oral Tablet; Assigned to Arm(s): Apixaban 2.5 mg twice daily and standard of care
C: Arm Label: LMWH arm; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin | Arm Label: UFH arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DRUG; Name: Nadroparin; Assigned to Arm(s): LMWH arm | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): UFH arm
D: Arm Label: nafamostat; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat Mesylate | Arm Label: Cnoxane; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Nafamostat Mesylate; Assigned to Arm(s): nafamostat

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development and Usability Testing of a Progressive WebApp for Women With Heart Disease
Brief Summary: The overall goal of this program of research is to develop and systematically evaluate an integrated smartphone and web-based intervention (at heart \[formerly called HEARTPA♀N\]) to provide evidence-informed symptom triage and self-management support to reduce pain and increase health-related quality of life (HRQoL) in women with heart disease. The investigators will use the individual and family self-management theory, mobile device functionality and the pervasive information architecture of mHealth interventions, and follow the sequential phased approach recommended by the Medical Research Council (MRC) to develop at heart (progressive WebApp). Funding was received from the Canadian Institutes of Health Research to develop the architecture and conduct usability testing (Phase 2, complete) to ensure it is easy to use, efficient and satisfying to operate. In Phase 3 (current proposal), feasibility in terms of implementation (accrual rates, acceptability and level of engagement) and initial estimation of effectiveness outcomes (estimates of magnitude of effect) will be evaluated in a pilot randomized controlled trial (RCT). The Phase 3 pilot study will enable the investigators to refine the prototype, inform the methodology, and calculate the sample size for a larger multi-site RCT (Phase 4, future work).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response System | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-Led Group Clinic Visits | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response System; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Nurse-Led Group Clinic Visits; Assigned to Arm(s): 2
B: Intervention Type: OTHER; Name: Peer Support; Assigned to Arm(s): N/A
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: at heart (changed from HEARTPA♀N during usability testing) | Intervention Type: BEHAVIORAL; Name: at heart (changed from HEARTPA♀N during usability testing); Assigned to Arm(s): Treatment
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-coordinated integrated care model for AF | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nurse-coordinated integrated care model for AF; Assigned to Arm(s): Intervention group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Exercise on Hand Function, on Activities of Daily Living (ADLs) Performance and Quality of Life of Patients With Systemic Lupus Erythematosus (SLE)
Brief Summary: A total of 240 consecutive SLE patients fulfilling the SLICC classification criteria was evaluated. Sixty two patients who met the inclusion criteria were randomly assigned to the exercise group (n=32) or the control group (n=30).

Patients in the exercise group performed a program of strengthening, stretching and resistance upper limbs exercises, of 30 minutes duration daily, for 12 weeks. Performance of daily activities was evaluated with the DASH and HAQ questionnaires, grip and pinch strength with the Jamar dynamometer and pinch gauge tools respectively, dexterity with the Purdue pegboard test and the quality of life with the LUPUSQoL questionnaire at 0, 6, 12 (end of the exercise program) and 24 weeks for both groups. SLE activity and cumulative organ damage were evaluated with the SLE disease activity index 2000 (SLEDAI-2K) and SLICC/ACR-DI, respectively.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Aerobic exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Anaerobic exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Aerobic exercise group, Anaerobic exercise group
B: Arm Label: EXERCISE GROUP; Type: EXPERIMENTAL; Interventions: Behavioral: HAND EXERCISE | Arm Label: CONTROL GROUP; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: HAND EXERCISE; Assigned to Arm(s): EXERCISE GROUP
C: Arm Label: Supervised physical exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised physical exercise | Arm Label: No supervised physical exercise; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised physical exercise; Assigned to Arm(s): Supervised physical exercise
D: Arm Label: Placebo plus SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 4 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 4 mg/kg | Arm Label: Belimumab 10 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus SOC | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 4 mg/kg; Assigned to Arm(s): Belimumab 4 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg plus SOC

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Perianal Fistulas in Crohn's Disease With Injection of Freshly Harvested Autologous Adipose Tissue
Brief Summary: Present study investigated the efficacy of injection of freshly collected autologous adipose tissue into perianal fistulas in patients with Crohn's disease. Adipose tissue collected by liposuction was injected into the perianal fistulas. Primary objective was complete clinical healing six months after treatment. Secondary objectives were reduced or ceased fistula secretion and complications to the treatment.


Options:
A: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Other: Cx601 | Arm Label: Placebo-control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline solution | Intervention Type: OTHER; Name: Cx601; Assigned to Arm(s): Treatment Arm | Intervention Type: OTHER; Name: Saline solution; Assigned to Arm(s): Placebo-control group
B: Arm Label: ASCs; Type: EXPERIMENTAL; Interventions: Drug: ASCs (Cx401, company code) | Arm Label: ASCs+fibrin glue; Type: EXPERIMENTAL; Interventions: Drug: ASCs (Cx401, company code), Drug: Fibrin adhesive | Arm Label: Fibrin glue; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fibrin adhesive | Intervention Type: DRUG; Name: ASCs (Cx401, company code); Assigned to Arm(s): ASCs, ASCs+fibrin glue | Intervention Type: DRUG; Name: Fibrin adhesive; Assigned to Arm(s): ASCs+fibrin glue, Fibrin glue
C: Arm Label: Mesenchymal Stem Cells; Type: EXPERIMENTAL; Interventions: Drug: Mesenchymal Stem Cells | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Mesenchymal Stem Cells; Assigned to Arm(s): Mesenchymal Stem Cells | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Treatment; Type: OTHER; Interventions: Procedure: Injection with freshly collected autologous adipose tissue | Intervention Type: PROCEDURE; Name: Injection with freshly collected autologous adipose tissue; Assigned to Arm(s): Treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The TESLA Trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke
Brief Summary: The primary objective of the trial is to establish the effectiveness of IAT (versus medical management) in patients with moderate-large infarcts (NCCT ASPECTS 2-5) at baseline, with adaptive enrichment to better define the upper limit of infarct volume for treatment eligibility. Furthermore, the investigators aim to determine whether certain subgroups of patients with large baseline infarcts will have a greater treatment benefit. Finally, the investigators will assess the agreement of ASPECTS scores between site investigators, the core imaging lab, and automated software.


Options:
A: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
B: Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intra-arterial Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Intra-arterial Therapy | Intervention Type: PROCEDURE; Name: Intra-arterial Therapy; Assigned to Arm(s): Intra-arterial Therapy
C: Arm Label: Best medical therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Endovascular Mechanical Thrombectomy | Intervention Type: DEVICE; Name: Endovascular Mechanical Thrombectomy; Assigned to Arm(s): Endovascular treatment
D: Arm Label: Group with endovascular treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Rescue endovascular therapy | Arm Label: Group without endovascular treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: No endovascular therapy | Intervention Type: PROCEDURE; Name: Rescue endovascular therapy; Assigned to Arm(s): Group with endovascular treatment | Intervention Type: PROCEDURE; Name: No endovascular therapy; Assigned to Arm(s): Group without endovascular treatment

Answer: B